Skip to main content
Mind Medicine (MindMed) Inc. logo

Mind Medicine (MindMed) Inc. — Investor Relations & Filings

Ticker · MNMD ISIN · CA60255C8850 LEI · 549300QY8KN1O6RPFJ13 US Manufacturing
Open in API
Filings indexed 439 across all filing types
Latest filing 2024-08-12 Capital/Financing Update
Country CA Canada
Listing US MNMD

About Mind Medicine (MindMed) Inc.

https://ir.mindmed.co/

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders. The company's research and development pipeline focuses on innovative treatments derived from psychedelics and other novel compounds. These candidates, which include substances with and without acute perceptual effects, are designed to target key neurotransmitter pathways. MindMed's mission is to deliver therapies that address unmet patient needs in psychiatry, with clinical programs investigating treatments for conditions such as Major Depressive Disorder.

Recent filings

Filing Released Lang Actions
424B5
Capital/Financing Update Classification · 100% confidence The document is a detailed prospectus supplement and base prospectus related to a public offering of common shares and pre-funded warrants by MindMed (Mind Medicine) Inc. It includes offering terms, underwriting details, risk factors, use of proceeds, and other information typical of a securities offering document. The document is filed pursuant to Rule 424(b)(5), which is a prospectus supplement filing under the Securities Act of 1933. It is not a financial report, earnings release, management discussion, or any other type of corporate report. It is specifically related to capital raising and securities issuance. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is not a mere announcement but a full prospectus supplement.
2024-08-12 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a detailed prospectus supplement and accompanying prospectus related to a securities offering, specifically common shares and pre-funded warrants. It includes sections such as "Use of Proceeds," "Dividend Policy," "Description of Securities," and detailed information about the company's business and clinical trials. The document references a shelf registration statement on Form S-3 filed with the SEC, which is typical for capital raising activities. The content focuses on the terms of the offering, risk factors, and legal matters related to the securities issuance. This type of document is a capital markets filing related to financing activities rather than a financial report, management discussion, or regulatory filing unrelated to capital raising. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and detailed content confirm it is not a mere announcement but the actual prospectus supplement document.
2024-08-09 English
FORM 8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated May 28, 2024, by Mind Medicine (MindMed) Inc. It announces the entry into a material definitive agreement for an 'at-the-market' equity program to sell up to $150 million of common shares. The document includes details about the sales agreement, termination of a prior sales agreement, and references to exhibits. There are no financial statements or detailed financial data presented, only an announcement of a financing arrangement. This fits the definition of a Capital/Financing Update (CAP) rather than a full financial report or other categories.
2024-06-28 English
S-3ASR
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 registration statement filed with the SEC, which is used for registering securities for public offering. It includes a base prospectus and an 'at the market offering' sales agreement prospectus supplement. The text describes the offering, issuance, and sale of common shares, warrants, debt securities, and units. It is not a financial report, earnings release, or management discussion but a capital markets filing related to fundraising and securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), indicating it is the actual filing, not just an announcement or a brief notice.
2024-06-28 English
S-8
Share Issue/Capital Change Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by Mind Medicine (MindMed) Inc. on June 28, 2024. Form S-8 is a registration statement used to register securities to be offered to employees under employee benefit plans such as stock option plans, restricted share unit plans, and employee share purchase plans. The document includes detailed information about the securities being registered, references to prior filings, and legal indemnification provisions. It is not a financial report, earnings release, proxy statement, or any other type of report listed in the filing definitions. Instead, it is a capital market filing related to the registration of shares for employee compensation plans, which falls under announcements regarding share issues or capital changes. Therefore, the appropriate classification is Share Issue/Capital Change (SHA). The document length and content confirm it is the registration statement itself, not merely an announcement of a report, so it is not RPA or RNS.
2024-06-28 English
4
Director's Dealing
2024-06-26 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.